|
English
|
正體中文
|
简体中文
|
2828323
|
|
???header.visitor??? :
32237727
???header.onlineuser??? :
4676
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"bowles d w"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; Chia-Chi Lin; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. |
| 國立成功大學 |
2022 |
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)
|
Brose, M.S.;Smit, J.W.A.;Lin, C.-C.;Tori, M.;Bowles, D.W.;Worden, F.;Shen, D.H.-Y.;Huang, S.-M.;Tsai, H.-J.;Alevizaki, M.;Peeters, R.P.;Takahashi, S.;Rumyantsev, P.;Guan, R.;Babajanyan, S.;Ozgurdal, K.;Sugitani, I.;Pitoia, F.;Lamartina, Lamartina L. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
